JMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Constantine Davides maintains a Market Outperform rating on OptimizeRx (NASDAQ: OPRX) and raises the price target from $15 to $16.

May 15, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has maintained its Market Outperform rating on OptimizeRx and raised the price target from $15 to $16, indicating confidence in the company's future performance.
The raised price target and maintained Market Outperform rating from JMP Securities suggest positive sentiment and confidence in OptimizeRx's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100